LLY

Eli Lilly andA

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1,325.00

+24.5% vs current

Most likely

Base case

45%

Probability

Target price

$1,160.00

+9.0% vs current

B-

Bear case

30%

Probability

Target price

$930.00

-12.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-29

AI commentary

Primary-source evidence is constructive but not enough for a standard-conviction thesis: Q1 results show strong revenue and earnings growth, while the notes financing is low-signal and the next meaningful forward evidence is still future pipeline or commercial-access confirmation. Recent news tone is favorable around obesity-drug access and Lilly's valuation milestone, but social coverage is unavailable in the packet and analyst revision evidence is not available, so the memo remains a cautious monitoring view.

RankAlpha Sentiment Codex - 2026-05-29

Open full AI memo

Evidence flagged

memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-04-30eventQ1 2026 results confirm continued cardiometabolic scale-up, but much is already reflectedMedium impact

The 2026 Q1 10-Q showed net product revenue of $18.453B versus $11.601B a year earlier and net income of $7.396B, confirming strong commercial scale in the core portfolio. Because this is already reported and Lilly trades at a premium valuation, it supports monitoring rather than a new high-conviction upgrade. [#10-Q-2026-04-30]

2026-05-20eventMay 20 notes financing is supportive but low-signal for operating momentumMedium impact

Lilly filed an 8-K on 2026-05-20 covering a notes sale under an underwriting agreement. The financing may add balance-sheet flexibility, but it is not a direct commercial, clinical, or regulatory catalyst. [#8-K-2026-05-20]

2026-12-31catalystFollow-on retatrutide and obesity pipeline updates remain the main forward de-risking checkpointMedium impact

The earlier TRIUMPH-1 retatrutide readout supports Lilly's next-generation obesity pipeline, but later TRIUMPH updates in 2026 remain the key test of whether pipeline breadth can sustain the current premium valuation. [#PR-2026-05-21]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-29 • Updated nightlySource: Internal modelMethodology